Pea, F, Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions, «CONTRIBUTIONS TO NEPHROLOGY», 2005, 147, pp. 35 - 46 [articolo]
Pea F.; Furlanut M., Levofloxacin PK/PD: From sequential therapy model to high dosage for critical patients, «JOURNAL OF CHEMOTHERAPY», 2004, 16, pp. 8 - 10 [articolo]
Pea F.; Viale P.; Lugano M.; Pavan F.; Scudeller L.; Rocca G.D.; Furlanut M., Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: A report of 2 cases, «AMERICAN JOURNAL OF KIDNEY DISEASES», 2004, 44, pp. 1097 - 1102 [replica/breve intervento]
Pea F.; Viale P.; Candoni A.; Pavan F.; Pagani L.; Damiani D.; Casini M.; Furlanut M., Teicoplanin in patients with acute leukaemia and febrile neutropenia: A special population benefiting from higher dosages, «CLINICAL PHARMACOKINETICS», 2004, 43, pp. 405 - 415 [articolo]
Pea, F; Viale, P; Furlanut, M I, Antimicrobial agents in elective surgery: prophylaxis or "early therapy"?, «JOURNAL OF CHEMOTHERAPY», 2003, 15, pp. 3 - 11 [articolo]
Pea F.; Russo D.; Michieli M.; Damiani D.; Fanin R.; Michelutti A.; Michelutti T.; Piccolrovazzi S.; Baccarani M.; Furlanut M., Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia, «CLINICAL PHARMACOKINETICS», 2003, 42, pp. 851 - 862 [articolo]
Pea F.; Pavan F.; Nascimben E.; Benetton C.; Scotton P.G.; Vaglia A.; Furlanut M., Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy, «ANTIMICROBIAL AGENTS AND CHEMOTHERAPY», 2003, 47, pp. 3104 - 3108 [articolo]
Furlanut M.; Brollo L.; Lugatti E.; Di Qual E.; Dolcet F.; Talmassons G.; Pea F., Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with respiratory tract infections, «JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY», 2003, 51, pp. 101 - 106 [articolo]
Pea F.; Di Qual E.; Cusenza A.; Brollo L.; Baldassarre M.; Furlanut M., Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia, «CLINICAL PHARMACOKINETICS», 2003, 42, pp. 589 - 598 [articolo]
Pea F.; Pavan F.; Di Qual E.; Brollo L.; Nascimben E.; Baldassarre M.; Furlanut M., Urinary Pharmacokinetics and Theoretical Pharmacodynamics of Intravenous Levofloxacin in Intensive Care Unit Patients Treated with 500 mg b.i.d. for Ventilator-Associated Pneumonia, «JOURNAL OF CHEMOTHERAPY», 2003, 15, pp. 563 - 567 [articolo]
Viale P.; Pea F., What is the Role of Fluoroquinolones in Intensive Care?, «JOURNAL OF CHEMOTHERAPY», 2003, 15, pp. 5 - 10 [articolo]
Pea F.; Licari M.; Baldassarre M.; Furlanut M., MEGX disposition in critically-ill trauma patients: Subsequent assessments during the first week following trauma, «FUNDAMENTAL & CLINICAL PHARMACOLOGY», 2002, 16, pp. 519 - 525 [articolo]
Pea F.; Bertolissi M.; Di Silvestre A.; Poz D.; Giordano F.; Furlanut M., TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients, «INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS», 2002, 20, pp. 326 - 332 [articolo]
Scotton P.G.; Pea F.; Giobbia M.; Baraldo M.; Vaglia A.; Furlanut M., Cerebrospinal fluid penetration of levofloxacin in patients with spontaneous acute bacterial meningitis, «CLINICAL INFECTIOUS DISEASES», 2001, 33, pp. e109 - e111 [articolo]
Baraldo M.; Pea F.; Poz D.; Albanese M.C.; Livi U.; Furlanut M., Cyclosporine dose fractioning might affect renal function in stable heart transplanted patients, «TRANSPLANTATION PROCEEDINGS», 2001, 33, pp. 3151 - 3153 [articolo]
